Nektar (NKTR) Q1 Loss Wider Than Expected, Sales Soar Y/Y
Zacks Investment Research | May 13, 2018 09:44PM ET
Nektar Therapeutics (NASDAQ:NKTR) reported a loss of 60 cents per share for the first quarter of 2018, which was wider than the Zacks Consensus Estimate of a loss of 52 cents and the year-ago figure of 42 cents due to higher R&D costs.
Nektar’s stock was up 2.8% on May 11 following the earnings release. Shares of Nektar have outperformed the industry so far this year. The stock has risen 33% while the industry is up 0.6%.
Quarterly revenues soared 53.8% from the year-ago period to $38 million. This upside can mainly be attributed to a $10 million milestone payment under the collaboration agreement with Shire plc (NASDAQ:SHPG) related to the approval of hemophilia drug, Adynovi, in Europe. The top line came in line with the Zacks Consensus Estimate.
Quarter in Detail
The top line comprised product sales, royalty revenues, non-cash royalty revenues besides license, collaboration and other revenues.
In the first quarter, product sales rose 32.4% to $6.3 million from $4.8 million a year ago. Moreover, non-cash royalty revenues increased 3.9% to $6.9 million.
The company reported royalty revenues of $11.1 million in the quarter under review, registering an improvement of 53.5% from $7.2 million a year ago.
License, collaboration and other revenues came in at $13.7 million compared with $6.1 million in the prior year, an upside of 125.3%.
Research and development (R&D) expenses escalated 62.8% to $99.4 million, primarily due to investments in pipeline including key candidates NKTR-358, NKTR-214 and NKTR-181.
General and administrative (G&A) expenses were up 56% to $18.7 million in the reported quarter primarily due to higher stock-based compensation.
Pipeline Update
The company received a major boost in February when it announced a global strategic collaboration agreement with Bristol-Myers Squibb (NYSE:BMY) . Per the agreement, the companies will jointly develop and commercialize Nektar’s lead immuno-oncology candidate, NKTR-214, in combination with Bristol-Myers’ Opdivo (nivolumab) and Opdivo plus Yervoy (ipilimumab).
Moreover, pursuant to the contract, the company received $1.0 billion in upfront payment and proceeds of $850 million from share purchase in April.
In the same month, Nektar began dosing in a phase I/II study – REVEAL – to evaluate a combination of its two candidates NKTR-262, a toll-like receptor agonist, and NKTR-214, an immuno-stimulatory CD122-biased agonist, in advanced or metastatic solid tumor cancers.
Moreover, the company has also collaborated with Takeda to develop NKTR-214 in combination with the latter’s TAK-659, a dual SYK and FLT-3 inhibitor, in liquid and solid tumors. First study under this collaboration is expected to start in the second half of 2018, which will evaluate the combination in non-Hodgkin lymphoma.
In May, Nektar initiated a dose ranging phase Ib study to evaluate NKTR-358, a regulatory T cell stimulator, in patients with systemic lupus erythematosus, an autoimmune disease. The company has a worldwide license agreement with Eli Lilly (NYSE:LLY) related to the development of NKTR-358.
Apart from these, the company’s pipeline includes two late stage candidates, Onzeald and NKTR-181.
Onzeald is currently under evaluation in a phase III (ATTAIN) study for the treatment of adults with advanced breast cancer, having brain metastases. The company is developing NKTR-181 for the treatment of chronic pain. A new drug application is expected to be filed with the FDA this month.
Get The News You Want
Nektar Therapeutics Price and EPS Surprise
Zacks Investment Research
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.